Company overview
Innogene Kalbiotech Pte. Ltd.
UEN
200306430D
Name
Innogene Kalbiotech Pte. Ltd.
Entity type
Local Company
UEN Issue Date
8 July 2003
Secondary SSIC Description
General Trading
Status
Live Company
incorporationDate
8 July 2003
Address
21, BUKIT BATOK CRESCENT, #28-79, WCEGA TOWER
Postal code
658065
Country
Singapore
Primary goods traded
- 72.5% — Blood, human or animal, antisera, other blood fractions and immunological products (300215)
- 23.7% — Blood, human or animal, antisera, other blood fractions and immunological products (300212)
- 2.9% — Medicaments (300490)
- 1.0% — Toxins, cultures of micro-organisms (excluding yeasts) and similar products (300290)
Main Trading Partners
| Partner | Type | Total Value | Percentage |
|---|---|---|---|
| PT Kalbe Farma | buyer | $15,707,537 | 28.87% |
| PT Kalbio Global Medika | seller | $150,000 | 0.28% |
Loading chart...
Loading chart...
Trade Data
| Data Source | HS Code | Description | Buyer | Buyer Country | Seller | Seller Country | ||
|---|---|---|---|---|---|---|---|---|
| 17 September 2025 | ID | 30021500 | Avamab 100 Mg/4 Ml (Bevacizumab 25 Mg Larutan Konsentrat Untuk Infus), Bn. 240577 | Kalbe Farma | ID | Innogene Kalbiotech Pte Limited | $106,250.00 | |
| 16 September 2025 | ID | 30021500 | Avamab 100 Mg/4 Ml (Bevacizumab 25 Mg Larutan Konsentrat Untuk Infus), Bn. 250414 | Kalbe Farma | ID | Innogene Kalbiotech Pte Limited | $510,000.00 | |
| 5 August 2025 | ID | 30021500 | Avamab 100 Mg/4 Ml (Bevacizumab 25 Mg Larutan Konsentrat Untuk Infus), Bn. 250295 | Kalbe Farma | ID | Innogene Kalbiotech Pte Limited | $514,080.00 | |
| 8 July 2025 | ID | 30021500 | Herzemab(trastuzumab 440 Mg)-Trastuzumab Combipack(with Bwfi),bn: Bf25000538 | Kalbe Farma | ID | Innogene Kalbiotech Pte Limited | $1,036,415.00 | |
| 3 July 2025 | ID | 30021500 | Avamab 100 Mg/4 Ml (Bevacizumab 25 Mg Larutan Konsentrat Untuk Infus), Bn. 250214 | Kalbe Farma | ID | Innogene Kalbiotech Pte Limited | $514,080.00 |
0 of 5 row(s) selected.